Article

MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicity

2022-03-17

Abstract excerpt

Tumor-specific antigens emerging through somatic genomic rearrangements, known as neoantigens, play a critical role in current anticancer immunotherapy. They may or may not elicit an immune response when presented on the tumor cell surface bound to the MHC-I molecule, whose strength has been assumed as an indicator of immunogenicity. Several in silico peptide-MHC-I binding affinity predictors are used to prioriti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9dc8a1fc-bd4b-5ac9-91b6-2f9d8853edfe
DOI: 10.1101/2022.03.14.484285

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicityDOI 10.1101/2022.03.14.484285Read

Beyond MHC binding: immunogenicity prediction tools to refine neoantigen selection in cancer patientsSemantic proximity Read

TSNAdb: A Database for Tumor-Specific Neoantigens from Immunogenomics Data AnalysisSemantic proximity Read

Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review)Semantic proximity Read

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapySemantic proximity Read

Characterizing neoantigens for personalized cancer immunotherapy.Semantic proximity Read

Computational Prediction and Validation of Tumor-Associated Neoantigens.Semantic proximity Read

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read

Computational cancer neoantigen prediction: current status and recent advancesSemantic proximity Read

Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic EpitopesSemantic proximity Read

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.Semantic proximity Read

Predicting T cell recognition of MHC class I restricted neoepitopesSemantic proximity Read

Advances and challenges in neoantigen prediction for cancer immunotherapySemantic proximity Read